SCHEMBL26239673

SCHEMBL26239673

CC(C)Nc1ncc(Cl)cc1C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.39
GABRB1 P18505 1/20 0.39
CRHR1 P34998 2/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
HTT P42858 3/20 0.35
HSD17B10 Q99714 2/20 0.35
TP53 P04637 2/20 0.35
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
GLP1R P43220 1/20 0.34
PDE10A Q9Y233 2/20 0.34
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
PPARG P37231 1/20 0.33
NCOA2 Q15596 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8007654 0.81 CRHR1 (0.48) CRHR1MEN1KMT2AHTTHSD17B10
SCHEMBL26239676 0.79 LMNA (0.34) HTTHSD17B10TP53SMN1; SMN2KDM4E
SCHEMBL15781884 0.79 PDE10A (0.41) CRHR1MEN1KMT2AHTTHSD17B10
SCHEMBL26239679 0.78 JAK2 (0.35) HTTSMN1; SMN2PDE10ALMNAIRAK4
SCHEMBL17131647 0.78 IRAK4 (0.43) CRHR1MEN1KMT2AHTTHSD17B10
SCHEMBL15781881 0.75 PDE10A (0.44) CRHR1MEN1KMT2AHTTHSD17B10
SCHEMBL8214469 0.75 GABRA1 (0.43) GABRA1GABRB1MEN1KMT2AHTT
SCHEMBL12356952 0.74 GABRA1 (0.46) GABRA1GABRB1MEN1KMT2AHTT
SCHEMBL23792399 0.73 CAMKK2 (0.43) MEN1KMT2AHSD17B10TP53HPGD
SCHEMBL15635181 0.73 DHODH (0.48) HSD17B10TP53KDM4EPDE10AMCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF PIC Therapeutics, Inc. 2023-12-14 US disclosed
US-11753403-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2023-09-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230399322-A1 EIF4E INHIBITORS AND USES THEREOF EIF4E, EIF4EBP1, EIF4A1 GABRA1 3961/4885GABRB1 3719/4885CRHR1 3391/4885
US-11753403-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 GABRA1 3961/4885GABRB1 3719/4885CRHR1 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.